## Giovanna Tosato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7977213/publications.pdf

Version: 2024-02-01

172 papers 11,429 citations

19608 61 h-index 30848 102 g-index

175 all docs

175 docs citations

175 times ranked 11046 citing authors

#	Article	IF	CITATIONS
1	Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood, 2003, 101, 1535-1542.	0.6	426
2	Defective Regulation of Epstein–Barr Virus Infection in Patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS-Related Disorders. New England Journal of Medicine, 1986, 314, 874-879.	13.9	390
3	Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Blood, 1999, 93, 4034-4043.	0.6	371
4	Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, 2006, 107, 931-939.	0.6	327
5	Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood, 2002, 99, 2703-2711.	0.6	315
6	Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth. Journal of Experimental Medicine, 1998, 188, 2349-2356.	4.2	299
7	Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. Journal of Clinical Oncology, 2000, 18, 2593-2602.	0.8	288
8	An Interleukinâ€6–Related Systemic Inflammatory Syndrome in Patients Coâ€Infected with Kaposi Sarcoma–Associated Herpesvirus and HIV but without Multicentric Castleman Disease. Clinical Infectious Diseases, 2010, 51, 350-358.	2.9	266
9	Mig, the Monokine Induced By Interferon- $\hat{I}^3$ , Promotes Tumor Necrosis In Vivo. Blood, 1997, 89, 2635-2643.	0.6	242
10	Defective EBV-Specific Suppressor T-Cell Function in Rheumatoid Arthritis. New England Journal of Medicine, 1981, 305, 1238-1243.	13.9	228
11	Involvement of Interleukin-10 (IL-10) and Viral IL-6 in the Spontaneous Growth of Kaposi's Sarcoma Herpesvirus-Associated Infected Primary Effusion Lymphoma Cells. Blood, 1999, 94, 2871-2879.	0.6	228
12	Hypoxia induces lytic replication of Kaposi sarcoma–associated herpesvirus. Blood, 2001, 97, 3244-3250.	0.6	220
13	Differential processing of stromal-derived factor- $1\hat{l}$ ± and stromal-derived factor- $1\hat{l}$ 2 explains functional diversity. Blood, 2004, 103, 2452-2459.	0.6	192
14	G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood, 2006, 108, 812-820.	0.6	184
15	Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12. Blood, 1999, 93, 1612-1621.	0.6	174
16	Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Blood, 1999, 93, 4034-4043.	0.6	172
17	Calreticulin and Calreticulin Fragments Are Endothelial Cell Inhibitors That Suppress Tumor Growth. Blood, 1999, 94, 2461-2468.	0.6	170
18	The Role of Mig, the Monokine Induced by Interferon-γ, and IP-10, the Interferon-γ–Inducible Protein-10, in Tissue Necrosis and Vascular Damage Associated With Epstein-Barr Virus-Positive Lymphoproliferative Disease. Blood, 1997, 90, 4099-4105.	0.6	162

#	Article	IF	CITATIONS
19	High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood, 2011, 117, 6977-6986.	0.6	149
20	Epstein-Barr Virus Infection and Immunoregulation in Man. Advances in Immunology, 1985, 37, 99-149.	1.1	144
21	Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood, 2013, 122, 4189-4198.	0.6	141
22	Differential Chemokine Expression in Tissues Involved by Hodgkin's Disease: Direct Correlation of Eotaxin Expression and Tissue Eosinophilia. Blood, 1999, 93, 2463-2470.	0.6	138
23	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clinical Infectious Diseases, 2016, 62, 730-738.	2.9	135
24	Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood, 2004, 103, 301-308.	0.6	130
25	Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. Journal of Leukocyte Biology, 1998, 64, 384-392.	1.5	125
26	Mast cell–derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. Journal of Clinical Investigation, 2004, 114, 1317-1325.	3.9	125
27	Essential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis. Advances in Cancer Research, 2012, 114, 21-57.	1.9	118
28	IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. International Immunology, 1993, 5, 1599-1608.	1.8	117
29	Detection of viral interleukin-6 in Kaposi sarcoma–associated herpesvirus–linked disorders. Blood, 2001, 97, 2173-2176.	0.6	114
30	B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood, 2005, 106, 795-802.	0.6	114
31	Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood, 2006, 107, 4650-4657.	0.6	113
32	Interleukin-15 Promotes Angiogenesisin Vivo. Biochemical and Biophysical Research Communications, 1997, 233, 231-237.	1.0	110
33	HHV-8–encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood, 2012, 119, 5173-5181.	0.6	110
34	A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12. Annals of the New York Academy of Sciences, 1996, 795, 158-167.	1.8	109
35	Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood, 2005, 105, 1992-1999.	0.6	109
36	Diagnosis of Atypical Cases of Infectious Mononucleosis. Clinical Infectious Diseases, 2001, 33, 83-88.	2.9	107

3

#	Article	lF	CITATIONS
37	A Syndrome of Peripheral Blood T-Cell Infection With Epstein-Barr Virus (EBV) Followed by EBV–Positive T-Cell Lymphoma. Blood, 1998, 91, 2085-2091.	0.6	101
38	Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphomas. Blood, 1999, 94, 4247-4254.	0.6	101
39	EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood, 2009, 114, 1707-1716.	0.6	99
40	Involvement of Interleukin-10 (IL-10) and Viral IL-6 in the Spontaneous Growth of Kaposi's Sarcoma Herpesvirus-Associated Infected Primary Effusion Lymphoma Cells. Blood, 1999, 94, 2871-2879.	0.6	97
41	Kaposi Sarcoma Herpesvirus Promotes Endothelial-to-Mesenchymal Transition through Notch-Dependent Signaling. Cancer Research, 2012, 72, 1157-1169.	0.4	96
42	Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1α in the circulation. Blood, 2005, 105, 4561-4568.	0.6	93
43	Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood, 2000, 96, 1599-1601.	0.6	85
44	The Epstein-Barr Virus and The Immune System. Advances in Cancer Research, 1987, 49, 75-125.	1.9	84
45	A Pilot Study of Cidofovir in Patients with Kaposi Sarcoma. Journal of Infectious Diseases, 2003, 187, 149-153.	1.9	84
46	Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood, 2012, 120, 4104-4115.	0.6	84
47	The Role of Chemokines in Hodgkin's Disease. Leukemia and Lymphoma, 2000, 38, 363-371.	0.6	83
48	Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 2000, 96, 1900-1905.	0.6	82
49	The Tensin-3 Protein, Including its SH2 Domain, Is Phosphorylated by Src and Contributes to Tumorigenesis and Metastasis. Cancer Cell, 2009, 16, 246-258.	7.7	81
50	HIV-1 Tat enhances Kaposi sarcoma–associated herpesvirus (KSHV) infectivity. Blood, 2004, 104, 810-814.	0.6	80
51	EphB2 and EphB4 receptors forward signaling promotes SDF-1–induced endothelial cell chemotaxis and branching remodeling. Blood, 2006, 108, 2914-2922.	0.6	80
52	Viral Interleukinâ€10 in Chronic Active Epsteinâ€Barr Virus Infection. Journal of Infectious Diseases, 1997, 176, 254-257.	1.9	78
53	Palmitoylation Controls Recycling in Lysosomal Sorting and Trafficking. Traffic, 2008, 9, 1984-1997.	1.3	77
54	Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood, 2001, 97, 2526-2527.	0.6	76

#	Article	IF	CITATIONS
55	Role of Human Cripto-1 in Tumor Angiogenesis. Journal of the National Cancer Institute, 2005, 97, 132-141.	3.0	76
56	Prostaglandin E2promotes degranulation-independent release of MCP-1 from mast cells. Journal of Leukocyte Biology, 2006, 79, 95-104.	1.5	75
57	Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood, 2006, 107, 3892-3901.	0.6	74
58	Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12. Blood, 1999, 93, 1612-1621.	0.6	70
59	Generation of Epsteinâ€Barr Virus (EBV)–Immortalized B Cell Lines. Current Protocols in Immunology, 2007, 76, Unit 7.22.	3.6	69
60	Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma–associated herpesvirus. Blood, 2001, 98, 3042-3049.	0.6	68
61	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. Cells, 2020, 9, 1583.	1.8	65
62	Interleukin-18, Interferon- $\hat{I}^3$ , IP-10, and Mig Expression in Epstein-Barr Virus-Induced Infectious Mononucleosis and Posttransplant Lymphoproliferative Disease. American Journal of Pathology, 1999, 155, 257-265.	1.9	64
63	Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells. Blood, 2007, 110, 2276-2285.	0.6	61
64	Biological aspects of Epstein–Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Critical Reviews in Oncology/Hematology, 2002, 44, 239-249.	2.0	59
65	Viral Interleukin-6: Role in Kaposi's Sarcoma-Associated Herpesvirus–Associated Malignancies. Journal of Interferon and Cytokine Research, 2011, 31, 791-801.	0.5	59
66	Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood, 2003, 102, 3900-3905.	0.6	58
67	Therapy Insight: AIDS-related malignanciesâ€"the influence of antiviral therapy on pathogenesis and management. Nature Clinical Practice Oncology, 2005, 2, 406-415.	4.3	57
68	Impaired Recruitment of Grk6 and $\hat{I}^2$ -Arrestin2 Causes Delayed Internalization and Desensitization of a WHIM Syndrome-Associated CXCR4 Mutant Receptor. PLoS ONE, 2009, 4, e8102.	1.1	55
69	MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1. Haematologica, 2012, 97, 818-826.	1.7	55
70	Regulation of CXCR4 by the Notch Ligand Delta-like 4 in Endothelial Cells. Cancer Research, 2008, 68, 1889-1895.	0.4	54
71	EphrinB2 controls vessel pruning through STAT1-JNK3 signalling. Nature Communications, 2015, 6, 6576.	5.8	54
72	B-cell-derived interleukin 1 (IL-1)-like factor. Cellular Immunology, 1985, 94, 406-417.	1.4	53

#	Article	IF	Citations
73	Derivation of Endothelial Cells from CD34â^'Umbilical Cord Blood. Stem Cells, 2004, 22, 385-395.	1.4	53
74	Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF- $\hat{l}_{\pm}$ and IFN- $\hat{l}_{3}$ . Journal of Leukocyte Biology, 2004, 76, 217-226.	1.5	51
75	Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A. Blood, 2008, 111, 4126-4136.	0.6	51
76	The Angiogenesis Inhibitor Vasostatin does not Impair Wound Healing at Tumor-Inhibiting Doses. Journal of Investigative Dermatology, 2001, 117, 1036-1041.	0.3	49
77	Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue Microarrays. Modern Pathology, 2001, 14, 1270-1276.	2.9	48
78	Human and Viral Interleukin-10 in Acute Epstein-Barr Virus-Induced Infectious Mononucleosis. Journal of Infectious Diseases, 1995, 171, 1347-1350.	1.9	47
79	Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood, 2008, 112, 1904-1911.	0.6	47
80	Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands. PLoS ONE, 2013, 8, e81445.	1.1	47
81	Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Science Signaling, 2016, 9, ra28.	1.6	44
82	Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Primary Effusion Lymphomas. Leukemia and Lymphoma, 2001, 41, 229-237.	0.6	43
83	The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1. Blood, 2010, 115, 3970-3979.	0.6	43
84	B-cell-derived interleukin-1 (IL-1)-like factor. Cellular Immunology, 1985, 94, 418-426.	1.4	41
85	State-of-the-Art Review: Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 137-145.	1.8	41
86	Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. Journal of Leukocyte Biology, 2008, 84, 994-1000.	1.5	39
87	EBV-NK Cells Interactions and Lymphoproliferative Disorders. Leukemia and Lymphoma, 1998, 29, 491-498.	0.6	38
88	Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunology, Immunotherapy, 2002, 51, 358-366.	2.0	38
89	Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood, 2000, 96, 1599-1601.	0.6	38
90	Neoplastic Conditions in the Context of HIV-1 Infection. Current HIV Research, 2004, 2, 343-349.	0.2	38

#	Article	IF	Citations
91	Association of Interleukin-6 in the Pathogenesis of Acutely Fatal SIVsmm/PBj-14in Pigtailed Macaques*. AIDS Research and Human Retroviruses, 1993, 9, 1123-1129.	0.5	37
92	PEGylation Potentiates the Effectiveness of an Antagonistic Peptide That Targets the EphB4 Receptor with Nanomolar Affinity. PLoS ONE, 2011, 6, e28611.	1.1	36
93	Gene Regulation and Functional Alterations Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded <i>ORFK13/vFLIP</i> in Endothelial Cells. Journal of Virology, 2009, 83, 2140-2153.	1.5	35
94	Tumor-Infiltrating Myeloid Cells Activate Dll4/Notch/TGF- $\hat{l}^2$ Signaling to Drive Malignant Progression. Cancer Research, 2014, 74, 2038-2049.	0.4	35
95	Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow. Journal of Clinical Investigation, 2016, 126, 4554-4568.	3.9	35
96	Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphomas. Blood, 1999, 94, 4247-4254.	0.6	33
97	Chronic persistent Epsteinâ€Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. British Journal of Haematology, 1996, 95, 116-122.	1.2	31
98	Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. Journal of Leukocyte Biology, 2003, 74, 880-888.	1.5	31
99	Increased Cellâ€Free Viral DNA in Fatal Cases of Chronic Active Epsteinâ€Barr Virus Infection. Clinical Infectious Diseases, 1999, 28, 906-906.	2.9	30
100	PART IV. Cytokine and Hormone ImmunotherapyTreatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity. Critical Reviews in Immunology, 2007, 27, 401-414.	1.0	28
101	Expression of the Epstein-Barr Virus Protein LMP1 Mediates Tumor Regression In Vivo. Blood, 1998, 91, 2491-2500.	0.6	27
102	Cytosolic Phospholipase A2Â and Cancer: A Role in Tumor Angiogenesis. Journal of the National Cancer Institute, 2010, 102, 1377-1379.	3.0	27
103	Effect of Fibroblast Growth Factor 2 on Stromal Cell-Derived Factor 1 Production by Bone Marrow Stromal Cells and Hematopoiesis. Journal of the National Cancer Institute, 2007, 99, 223-235.	3.0	26
104	FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood, 2007, 109, 1363-1372.	0.6	26
105	Novel Anti-Inflammatory Properties of the Angiogenesis Inhibitor Vasostatin. Journal of Investigative Dermatology, 2007, 127, 65-74.	0.3	26
106	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. Journal of Virology, 2016, 90, 368-378.	1.5	26
107	Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas. Blood, 2000, 95, 1109-1110.	0.6	25
108	Adult human circulating CD34â^'Linâ^'CD45â^'CD133â^' cells can differentiate into hematopoietic and endothelial cells. Blood, 2011, 118, 2105-2115.	0.6	24

#	Article	IF	Citations
109	Regulation of angiogenesis in malignancies associated with Epstein–Barr virus and Kaposi's sarcoma-associated herpes virus. Future Microbiology, 2009, 4, 903-917.	1.0	22
110	Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1. Oncogene, 2020, 39, 4603-4618.	2.6	22
111	Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders. Current Drug Targets Infectious Disorders, 2003, 3, 115-128.	2.1	22
112	Differential Chemokine Expression in Tissues Involved by Hodgkin's Disease: Direct Correlation of Eotaxin Expression and Tissue Eosinophilia. Blood, 1999, 93, 2463-2470.	0.6	22
113	Pathogenesis and manifestations of human herpesvirus-8-associated disorders. Seminars in Hematology, 2003, 40, 143-153.	1.8	21
114	Infectious mononucleosis as a disease of early childhood in Japan caused by primary Epsteinâ€Barr virus infection. Pediatrics International, 1997, 39, 166-171.	0.2	20
115	EphrinB2 regulates the emergence of a hemogenic endothelium from the aorta. Scientific Reports, 2016, 6, 27195.	1.6	20
116	Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Seminars in Immunopathology, 1998, 20, 405-423.	4.0	19
117	8 Epstein-Barr virus as an agent of haematological disease. Best Practice and Research: Clinical Haematology, 1995, 8, 165-199.	1.1	18
118	Regression of Experimental Human Leukemias and Solid Tumors Induced by Epstein-Barr Virus-Immortalized B Cells. Leukemia and Lymphoma, 1995, 19, 267-276.	0.6	18
119	Human herpesvirus 8+ polyclonal <scp>l</scp> g <scp>M</scp> ĵ» <scp>B</scp> â€cell lymphocytosis mimicking plasmablastic leukemia/lymphoma in <scp>HIV</scp> â€infected patients. European Journal of Haematology, 2013, 91, 497-503.	1.1	18
120	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. Clinical Cancer Research, 2019, 25, 4238-4247.	3.2	17
121	Chemokine Gene Expression and Clonal Analysis of B Cells in Tissues Involved by Lymphoid Interstitial Pneumonitis from HIV-Infected Pediatric Patients. Modern Pathology, 2001, 14, 929-936.	2.9	16
122	Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies. Journal of the National Cancer Institute, 2005, 97, 705-707.	3.0	16
123	Pathogenesis and manifestations of human herpesvirus-8-associated disorders. Seminars in Hematology, 2003, 40, 143-153.	1.8	15
124	Ephrin ligands and Eph receptors contribution to hematopoiesis. Cellular and Molecular Life Sciences, 2017, 74, 3377-3394.	2.4	14
125	Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration. International Journal of Cancer, 2017, 140, 1597-1608.	2.3	14
126	Lymphatic Regeneration: New Insights From VEGFR-3 Blockade. Journal of the National Cancer Institute, 2005, 97, 2-3.	3.0	13

#	Article	IF	Citations
127	Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression. Journal of the National Cancer Institute, 2018, 110, 390-399.	3.0	13
128	DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis. Oncogene, 2019, 38, 7046-7059.	2.6	13
129	Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth. EMBO Molecular Medicine, 2021, 13, e14089.	3.3	13
130	NF-κB Activation Stimulates Transcription and Replication of Retrovirus XMRV in Human B-Lineage and Prostate Carcinoma Cells. Journal of Virology, 2011, 85, 3179-3186.	1.5	12
131	Development of EBV-Positive T-cell Lymphoma Following Infection of Peripheral Blood T Cells with EBV. Leukemia and Lymphoma, 1999, 34, 603-607.	0.6	11
132	Contribution of automated hematology analysis to the detection of apoptosis in peripheral blood lymphocytes. Cytometry, 2000, 42, 209-214.	1.8	11
133	Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders. Expert Review of Anti-Infective Therapy, 2004, 2, 213-225.	2.0	11
134	Tumor Cell Populations Differ in Angiogenic Activity: A Model System for Spontaneous Angiogenic Switch Can Tell Us Why. Journal of the National Cancer Institute, 2006, 98, 294-295.	3.0	11
135	Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. Molecular Oncology, 2019, 13, 2441-2459.	2.1	11
136	Targeting the Tumor Vasculature to Improve the Efficacy of Oncolytic Virus Therapy. Journal of the National Cancer Institute, 2007, 99, 1739-1741.	3.0	10
137	Investigation of the interactions between the EphB2 receptor and SNEW peptide variants. Growth Factors, 2014, 32, 236-246.	0.5	10
138	A Merging of Disciplines. Annals of the New York Academy of Sciences, 1989, 557, xv.	1.8	9
139	Neuropilin-2: A New Molecular Target for Antiangiogenic and Antitumor Strategies. Journal of the National Cancer Institute, 2008, 100, 81-83.	3.0	9
140	Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas. Journal of the National Cancer Institute, 2017, 109, .	3.0	9
141	Interferon-Â Is Implicated in the Transcriptional Regulation of Vascular Endothelial Growth Factor. Journal of the National Cancer Institute, 2003, 95, 420-421.	3.0	8
142	Contribution of Viral Mimics of Cellular Genes to KSHV Infection and Disease. Viruses, 2014, 6, 3472-3486.	1.5	7
143	Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis. Blood, 2010, 116, 3099-3107.	0.6	6
144	Inactivation of axon guidance molecule netrin-1 in human colorectal cancer by an epigenetic mechanism. Biochemical and Biophysical Research Communications, 2022, 611, 146-150.	1.0	6

#	Article	IF	CITATIONS
145	A Monocyteâ€derived B Cell Growth Factor Is IFNâ€Î² <sub>2</sub> /BSFâ€2/ILâ€6 <sup>a</sup> . Annals of the Ne York Academy of Sciences, 1989, 557, 181-191.	.y8	5
146	Novel insights into endothelial cell malignancies. Oncotarget, 2018, 9, 37468-37470.	0.8	4
147	Notch and TGFÎ <sup>2</sup> . Oncolmmunology, 2014, 3, e29029.	2.1	3
148	Iterative epigenomic analyses in the same single cell. Genome Research, 2021, 31, 1819-1830.	2.4	3
149	Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Seminars in Immunopathology, 1998, 20, 405-423.	4.0	3
150	Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 2000, 96, 1900-1905.	0.6	3
151	A Mechanism of T Cell Regulation of Epstein-Barr Virus Latency. Cellular Immunology, 1993, 147, 256-266.	1.4	2
152	Heterotransplantation of Human Burkitt's Lymphoma Cell Lines in Athymic Nude Mice: Tumor-Host Relationships. Pathobiology, 1993, 61, 164-172.	1.9	2
153	Calreticulin and Tumor Suppression. Molecular Biology Intelligence Unit, 2003, , 162-179.	0.2	2
154	Expression of the Epstein-Barr Virus Protein LMP1 Mediates Tumor Regression In Vivo. Blood, 1998, 91, 2491-2500.	0.6	2
155	Antisense transcription from lentiviral gene targeting linked to an integrated stress response in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 28, 877-891.	2.3	2
156	Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders. Current Drug Targets Cardiovascular & Haematological Disorders, 2003, 3, 81-96.	2.0	1
157	Conflicting Results from Clinical Observations and Murine Models: What Is the Role of Plasminogen Activators in Tumor Growth?. Journal of the National Cancer Institute, 2006, 98, 726-727.	3.0	1
158	Characterization of Semaphorin 6A-Mediated Effects on Angiogenesis Through Regulation of VEGF Signaling. Methods in Molecular Biology, 2017, 1493, 345-361.	0.4	1
159	Cell-Mediated Immunity. Clinical Topics in Infectious Disease, 1989, , 100-116.	0.2	1
160	Granulocyte Infiltration and Expression of the Pro-angiogenic Bv8 Protein in Experimental EL4 and Lewis Lung Carcinoma Tumors. Cureus, 2013, 5, 82.	0.2	1
161	A Syndrome of Peripheral Blood T-Cell Infection With Epstein-Barr Virus (EBV) Followed by EBV–Positive T-Cell Lymphoma. Blood, 1998, 91, 2085-2091.	0.6	1
162	Bone marrow niches in myelodysplastic syndromes. , 2021, 7, .		1

#	Article	IF	CITATIONS
163	Development of Opportunistic Non-Hodgkin�s Lymphomas in Severely Immunosuppressed HIV-Infected Patients Receiving Long-Term Antiretroviral Therapy., 1992,, 196-206.		0
164	Introduction: Herpesviruses in hematology. Seminars in Hematology, 2003, 40, 105-106.	1.8	0
165	Distinct Human and Viral Interleukin-6 Profiles and Other Viral and Immunologic Abnormalities In KSHV-Associated Multicentric Castleman Disease: Relationship with Disease Activity and Individual Disease Manifestations. Blood, 2011, 118, 1573-1573.	0.6	0
166	Primary Effusion Lymphoma. , 2013, , 1-7.		0
167	Phase I/II study of the safety, pharmacokinetics, and efficacy of pomalidomide in the treatment of Kaposi sarcoma in individuals with or without HIV Journal of Clinical Oncology, 2013, 31, TPS10595-TPS10595.	0.8	0
168	Primary Effusion Lymphoma. , 2014, , 195-205.		O
169	Monocytes and a Monocyte Product Regulate Epstein-Barr Virus-Induced B Cell Activation. , 1987, , 379-383.		0
170	Growth Stimulation and Immunoglobulin (Ig) Secretion in Epstein-Barr Virus (Ebv)-Infected B Cells by Interleukin 6 (IL-6)., 1989,, 227-229.		0
171	Primary Effusion Lymphoma. , 2018, , 1749-1755.		0
172	Reusable Single Cell for Iterative Epigenomic Analyses. Journal of Visualized Experiments, 2022, , .	0.2	0